Impact of Biomarker Expression, Treatment Response, and Survival Outcomes in Breast Cancer Patients: A Clinical and Translational Medicine Approach

Abstract

Although breast cancer is not as common or fatal among women as many other cancers, innovative focus is being given to personalised and precision cancer treatment. This research investigates how expression of these biomarkers affects breast cancer patients in the clinical and translational medicine landscape, including their treatment response and survival. Some important markers exist for predicting disease outcomes and for treatment, such as the receptor for human epidermal growth factor, and the estrogen and progesterone receptors. The study uses a quantitative clinical design, and data from patient records and laboratory assays are used to explore the relationships among biomarker profiles and therapy outcomes. The survival data is analysed with sophisticated statistical methods and significant molecular predictors identified. Our findings are expected to add to the body of evidence focused on translating research from the bench to the bedside with the ultimate purpose of optimizing cancer patient care and survival. The study highlights the need for incorporating biomarker-based approaches into clinical practice as a tool to improve breast cancer treatment.